PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors (Q39644716)

13 September 2017

PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors (English)

1 reference

13 September 2017

1 reference

10

1 reference

13 September 2017

12

Jorge S Reis-Filho

1 reference

13 September 2017

Rachael Natrajan

4

0 references

Alan Ashworth

series ordinal

11

object named as

Alan Ashworth

1 reference

13 September 2017

6

Felipe C Geyer

1 reference

13 September 2017

5

Maryou B Lambros

1 reference

13 September 2017

7

Radost Vatcheva

1 reference

13 September 2017

1

Konstantin J Dedes

1 reference

13 September 2017

3

Ana M Mendes-Pereira

1 reference

13 September 2017

2

Daniel Wetterskog

1 reference

13 September 2017

Kay Savage

8

1 reference

PubMed ID

20944090

13 September 2017

Alan Mackay

series ordinal

9

1 reference

PubMed ID

20944090

13 September 2017

language of work or name

English

0 references

publication date

1 October 2010

1 reference

Science Translational Medicine

13 September 2017

1 reference

13 September 2017

2

1 reference

13 September 2017

53ra75

1 reference

13 September 2017

53

1 reference

13 September 2017

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

Systemic therapy for recurrent endometrial cancer: a review of North American trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

Tenets of PTEN tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

PTEN1 is frequently mutated in primary endometrial carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

A coding-independent function of gene and pseudogene mRNAs regulates tumour biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

Essential role for nuclear PTEN in maintaining chromosomal integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

Targeted therapy for cancer using PARP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

PARP inhibition: PARP1 and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

Molecular and pathologic aspects of endometrial carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

Combined PTEN and p27kip1 protein expression patterns are associated with obesity and prognosis in endometrial carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

Resistance to therapy caused by intragenic deletion in BRCA2

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

Sub-nuclear localization of Rad51 in response to DNA damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

Cellular redistribution of Rad51 in response to DNA damage: novel role for Rad51C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

Gonadotropin-releasing hormone type II antagonists induce apoptotic cell death in human endometrial and ovarian cancer cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

Establishment and characterization of a poorly differentiated lethal human endometrial carcinoma cell line (NOU-1) with karyotype 46,XX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

PPM1D is a potential therapeutic target in ovarian clear cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

Tiling path genomic profiling of grade 3 invasive ductal breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

MSI-low, a real phenomenon which varies in frequency among cancer types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

Establishment of a new human cell line (EN) with TP53 mutation derived from endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001538

10.1126/SCITRANSLMED.3001538

21 January 2018

Identifiers

DOI

1 reference

13 September 2017

1 reference

PubMed ID

20944090